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Abstract The human type I interferons, including at least 12 
IFN-as, IFN-P and IFN-co, bind to a receptor (IFNAR) 
composed of at least two transmembrane subunits, IFNAR-1 
and IFNAR-2. The contributions of the receptor subunits to 
ligand binding were investigated by measuring the binding 
properties of IFNAR-1 or IFNAR-2 alone, or when co-
expressed. The affinity of IFNAR-2 for IFN-ct2 was increased 
by the co-expression of IFNAR-1, which itself binds ligand very 
weakly. Most type I IFNs inhibited the binding of IFN-ot2 to 
IFNAR-2 alone with IC50 values of 2-20 nM. For cells co-
expressing IFNAR-1 and IFNAR-2, the IC50 values decreased 3 -
20-fold for various ligands, relative to their values on IFNAR-2 
alone. Thus, while IFNAR-2 plays the major role in affinity 
determination and differential recognition of type I IFNs, 
IFNAR-1 modulates both the ligand affinity and selectivity of 
the IFNAR-l/IFNAR-2 receptor complex. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Type I interferons (IFN-as, IFN-p\ IFN-co)2 bind a com-
mon receptor, the type I interferon receptor, denoted IFNAR 
[1-3]. The type I I F N receptor has perhaps the largest number 
of natural ligands of all cytokine receptors, and the differen-
tial binding and functional activation of cells by type I IFNs 
is of considerable interest. 
IFNAR is composed of at least two subunits, IFNAR-1 
and IFNAR-2, which are members of the class II cytokine 
receptor family [4]. Both subunits participate directly in ligand 
binding and intracellular signaling. Human IFNAR-1 (Hu-
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2We adopt the nomenclature for type I receptors suggested by the 
Nomenclature Committee of the International Society for Interferon 
and Cytokine Research. IFNAR-1 corresponds to previous designa-
tions of: IFNAR, IFN-cxRl, IFN receptor a subunit; IFNAR-2 cor-
responds to previous designations of IFN-a/p receptor, IFN-aR2, 
IFN receptor (3 subunit. The two transmembrane variants of IF-
NAR-2, denoted IFNAR-2b and IFNAR-2c, have previously been 
called either IFNAR 2-1 and IFNAR 2-2 [21], or IFN-a/p receptor 
short form (ps) and long form (PL), respectively [20]. For interfer-
ons used in our study, we follow the recommended international no-
menclature (G. Allen and M.O. Diaz (1996) J. Interferon Cytokine 
Res. 16, 181-184): IFN-aA = IFN-a2a; IFN-aB2 = IFN-oc8b; IFN-
aD = IFN-cxlb. For readers' ease, the nomenclature is simplified to 
IFN-a2, IFN-a8 and IFN-ocl, respectively. For published citations, 
we maintain the nomenclature used by those authors. 
IFNAR-1) [5] has weak intrinsic affinity for at least two 
IFNs, IFN-a2 and -a8 [6,7]. Its expression confers on rodent 
cells limited responsiveness and binding of human type I IFNs 
[5], and enhances the ability of monkey-derived COS cells to 
bind human IFNs [8]. In contrast to HuIFNAR-1, the bovine 
homologue (BoIFNAR-1) fortuitously binds human IFN-as 
with high affinity [6,9,10]. The ability of antibodies against 
HuIFNAR-1 to block the binding of various type I interfer-
ons to human cells [11,12] suggests that IFNAR-1 is involved 
in a complex that binds all type I interferons. The importance 
of IFNAR-1 was demonstrated most dramatically in ifnar-10^ 
('knockout') mice, which do not respond to type I IFNs [13-
15]. Its role in signaling derives, at least in part, from its 
binding of the cytoplasmic tyrosine kinase Tyk2 [16,17], and 
possibly other factors (e.g. [18]). 
HuIFNAR-2 [19] has three molecular forms generated by 
alternative splicing: a soluble secreted protein (IFNAR-2a), 
and two transmembrane forms, IFNAR-2b and -2c ('short 
form' and 'long form', respectively), which have identical ex-
tracellular and transmembrane domains, but differ in their 
cytoplasmic domains [19-22]. IFNAR-2 binds IFNs, including 
aB, aC and [3, with the K& for IFN-a2 being in the nM range 
[20-22]. In the presence of IFNAR-1, only the IFNAR-2c 
form appears to confer signaling and biological function 
[19-22], presumably from its ability to recruit the Jakl tyro-
sine kinase, and the latent transcription factors Statl and 
Stat2 (reviewed in [23]). 
The relative contributions of IFNAR-1 and IFNAR-2 to 
the IFN binding characteristics of the cellular IFNAR com-
plex are not known. For murine cells co-expressing Hu-
IFNAR-1 and HuIFNAR-2, the affinity of HuIFN-a2 is 
about 5-10-fold higher than for murine cells transfected 
only with HuIFNAR-2 [20,22], but the binding of other 
type I IFNs has not been systematically investigated. We 
have expressed HuIFNAR-1 and HuIFNAR-2, both individ-
ually and together, at high levels in COS cells, and have ex-
amined the interactions of these cloned receptors and the na-
tive receptor complex on human Daudi cells with a wide 
variety of human type I IFNs. We have thereby demonstrated 
variations in the relative contributions of the two IFNAR 
subunits for different type I IFNs: while IFNAR-2 has higher 
affinity and some selectivity for ligands, IFNAR-1 modulates 
both the affinity and the differential selectivity of the receptor 
complex. 
2. Materials and methods 
2.1. Reagents and antibodies2 
The HuIFNAR-1 cDNA, HuIFNAR-2b cDNA and HuIFNAR-2c/ 
pcDEF3 construct were provided by Dr. Sidney Pestka (this Depart-
ment), as were the interferons: !FN-cx2a (=IFN-aA; 1.56X108 IU/ 
mg), IFN-a8b (=IFN-aB2; 4.95X108 IU/mg), and IFN-odb (=IFN-
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
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ocD; 7.63 X 107 IU/mg). The synthetic consensus IFN protein, me-
thionyl- IFN-aConl (1 X 109 IU/mg), was from Dr. Milton Taylor 
(Indiana University), originally from Dr. Lawrence Blatt (Amgen 
Corp.). IFN-co (3X108 IU/mg) was from Dr. G.R. Adolf (Bender 
Wien, Vienna, Austria). CHO-derived IFN-0 and the EA12 anti-
IFNAR-1 monoclonal antibody were from Dr. Leona Ling (Biogen 
Corp., Cambridge, MA). The anti-HuIFNAR-1 4B1 monoclonal anti-
body was provided by Dr. Ed Croze (Berlex, Richmond, CA). The 
HuIFNAR-2 antibody IFNaRpi [24] was from Dr. Oscar R. Cola-
monici (University of Tennessee, Memphis, TN). The recombinant 
fusion protein ('immunoadhesin') of the extracellular domain of hu-
man IFNAR-2 with the human constant heavy immunoglobulin do-
main, produced in CHO cells and referred to as 'HuIFNAR-2/Ig', was 
supplied by Dr. Laura Runkel (Biogen, Inc.). 
The HuIFN-aA analogue IFN-aA-Pl [25] was phosphorylated to 
high radiospecific activity with [y-32P]ATP and bovine heart cAMP-
dependent protein kinase. For consistency with international nomen-
clature, [32P]IFN-cxA-Pl is referred to as [32P]IFN-a2. 
2.2. Plasmid construction and DNA transfections 
IFNAR-1, IFNAR-2b, and IFNAR-2c were transiently expressed 
from the EF- la promoter in the vectors pEF-BOS-CS [26] or pcDEF3 
[26], derived from pEF-BOS [27] or pcDNA3 (InVitrogen, Inc.), re-
spectively. COS-1 cells [28], derived from a simian kidney line, were 
transfected with plasmids by the DEAE-Dextran/DMSO shock pro-
tocol [10,29,30], and assayed after growth for 2-3 days. 
2.3. Saturation binding and competition curves 
Saturation binding were performed as described [10]. Briefly, COS 
cells were trypsinized and resuspended at 1-5 XlO6 cells/ml. Aliquots 
of cells with and without excess cold IFN (1-3 ug/mi) were combined 
with [32P]IFN-a2, serially diluted, and incubated for 1 h at room 
temperature. Cell-bound [32P]IFN-a2 was separated from unbound 
by brief centrifugation, and bound and free radioactivity were meas-
ured. For competition binding assays, cells were combined with non-
radioactive IFNs (generally 4-fold serial dilutions) in addition to 
[32P]IFN-a2. Binding was generally measured in triplicate or quadru-
plicate. Occasional points more than 2 standard deviations from the 
mean were omitted from the analysis. Suppliers' determinations of 
IFN concentration (in mg/ml) were used for all calculations. 
Data were analyzed by non-linear regression to one- or two-site 
binding or competition models, using the program Prism v.2.01 
(GraphPad Software, Inc., San Diego, CA). Data sets were analyzed 
in two ways: (1) without any constraints, and (2) with the constraints 
that all curves in a single experiment have the same total binding in 
the absence of competitive ligand, and the same non-specific binding 
in the presence of saturating amounts of any competitor. Reported 
IC50 values and Figures are for constrained fits, unless the goodness 
of fit (R2) was substantially better in the absence of constraints (e.g. 
Fig. 3B). 
2.4. Solid-phase radioligand assay (RLA) 
For binding of IFNs to the IFNAR-2/Ig immunoadhesin, the pro-
tocol was modified from an ELISA protocol of Mohammad R. Zafari 
(Biogen, Inc.). Immulon 2 plates (Dynatech Laboratories) were coated 
with 50 ul of 5 ng/ml of AffiniPure goat anti-human IgG Fey fragment 
(Jackson ImmunoResearch). After 1-2 h, the wells were blocked with 
BSA (5 mg/ml) and 1% normal goat serum (Jackson ImmunoRe-
search) in PBS. Wells were washed once with PBS with 0.05% Tween 
20 and twice with PBS. The recombinant HuIFNAR-2/Ig fusion pro-
tein was added (50 ul of 1.25 (ig/ml PBS), incubated for 1 h at room 
CM £ 
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Fig. 1. Binding of [32P]IFN-a2 to transfected COS cells. Binding as-
says were performed as described on COS cells transfected with: 
HuIFNAR-1/pEF-BOS-CS ( T ) ; HuIFNAR-2b/pEF-BOS-CS ( ♦ ) ; 
HuIFNAR-1/pEF-BOS-CS and HuIFNAR-2b/pEF-BOS-CS (•); 
vector pEF-BOS-CS (lacking any insert) ( A ) . 
temperature, and washed. For competition binding assays, 50 ul PBS 
was added to each well, followed by approximately 1X 105 cpm of 
[32P]IFN-a2 and 50 ul of specific dilutions of different cold IFNs. 
After 1 h, plates were washed as described to remove unbound 
[32P]IFN-a2. Bound [32P]IFN-a2 was eluted with 1% SDS at 55°C 
for 10 min, and radioactivity was measured. 
2.5. Flow cytometric analysis of receptor surface expression 
Transfected cells were resuspended in 5% DMEM with 0.1 mg/ml 
human IgG. Cells (25 ul) were incubated for 1 h at 4°C with 0.12-0.25 
ug (25 ul) of primary antibody (anti-IFNAR-1 antibodies 4B1 or 
EA12, or anti-IFNAR-2 antibody IFNaRpi [24]), medium, or unre-
lated isotype-matched IgG. The cells were washed with PBS and re-
suspended in 0.125 ug (50 ul) of secondary antibody (R-Phycoery-
thrin-conjugated F(ab')2 Goat Anti-Mouse IgG; Jackson 
ImmunoResearch) and incubated for 1 h. The cells were washed 
and resuspended in 500 ill PBS for analysis with a Coulter Epics 
Profile II cell sorter. 
3. Results 
3.1. Transient expression of IFNAR subunits in COS cells and 
binding of [32P]IFN-a2 
The expression of IFNAR subunits on COS cells was ana-
lyzed by ligand binding, and by detection of surface receptors 
by flow cytometry. The transfection of COS cells with 
IFNAR-2b alone leads to very large increases in binding of 
[32P]IFN-cx2 when compared to COS cells transfected with 
vector alone, amounting to an average 16-25-fold increase 
in the calculated number of binding sites (Fig. 1; Table 1). 
These IFNAR-2 sites have an average Aj of about 7.9 nM, 
which is a somewhat lower affinity than the native COS re-
ceptor which is present at much lower abundance. The trans-
fection of IFNAR-1 alone into COS cells leads to a slight 
Table 1 
Binding of [32P]IFN-a2 to COS cells with human IFNAR components 
Transfected receptor Ki (nM) Receptors/cell (XlO4) 
Average Range Average Range 
N 
None 
IFNAR-1 
IFNAR-2b 
IFNAR-(l+2b) 
1.7 
1.8 
7.9 
3.1 
1.0-2.7 
2.7-11.7 
1.8^1.3 
1.3 
1.9 
56.0 
33.0 
1.8-2.1 
23-89 
22-49 
Daudi cells 0.27 1.1 
N is the number of independent experiments. 
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Fig. 2. Competition binding of type I interferons against [32P]IFN-
a2. The non-radioactive interferons were: IFN-a2 (■); IFN-a8 
( A ) ; IFN-al ( T ) and IFN-p (♦). Samples were: (A) soluble 
IFNAR-2/Ig fusion protein in a solid phase radioligand assay for-
mat; (B) COS cells transfected with IFNAR-2b; (C) COS cells co-
transfected with IFNAR-1 and IFNAR-2b. All curves were con-
strained to a common value for binding in the absence of 
competitor IFN and a common value for the non-specific binding 
(see Section 2 for discussion). 
increase over native COS cells in the number of sites, as re-
ported previously [8]; the increase is so small, however, that it 
is not known whether this binding is to the transfected 
IFNAR-1 alone, or to a complex of ectopic IFNAR-1 with 
endogenous COS receptor subunits. Compared to COS cells 
or COS cells transfected with IFNAR-1 alone, cells cotrans-
fected with IFNAR-1 and IFNAR-2b have greatly increased 
binding of [32P]IFN-oc2, but characterized by a reproducibly 
2-3-fold higher affinity (3.1 nM) than that of COS cells trans-
fected only with IFNAR-2b. Similar binding data were ob-
tained with IFNAR-2c (data not shown), which differs from 
IFNAR-2b only in its cytoplasmic domain. 
The cell surface expression of IFNAR-1 and IFNAR-2 was 
verified by flow cytometry (data not shown; see Section 2). 
This was particularly important for IFNAR-1, since its intrin-
sic binding of IFNs is poor. In these experiments, the surface 
expression of IFNAR-1 and IFNAR-2 are comparable: gen-
erally, 15-25% of transfected COS cells have fluorescence 10-
100 times higher than negative controls. Negative controls 
included untransfected cells, mock-transfected cells, trans-
fected cells reacted only with secondary antibody, and 
IFNAR-transfected cells reacted with an isotype-matched, un-
related primary antibody, but with the secondary antibody. 
The large enhancement in ligand binding by cells expressing 
IFNAR-2, either alone or with IFNAR-1, compared to COS 
cells expressing only IFNAR-1, permits the confident use of 
this transient transfection system in the current studies. 
3.2. Binding of type I IFNs to IFNAR-2 
The ligand binding properties of IFNAR-2 expressed in 
COS cells were examined and compared to the properties of 
a soluble construct of IFNAR-2 (IFNAR-2/Ig) measured in a 
plate format, radioligand assay (RLA) (cf. Figs. 2A and 3A 
Log IFN (M) 
Fig. 3. Competition binding of type I interferons against [32P]IFN-
a2. The non-radioactive interferons were: IFN-a2 (■); IFN-aConl 
( A ) ; and IFN-co (♦). Samples were: (A) soluble IFNAR-2/Ig fu-
sion protein in a solid phase radioligand assay format; (B) COS 
cells transfected with IFNAR-2c; (C) COS cells cotransfected with 
IFNAR-1 and IFNAR-2c. Curves A and C were constrained to a 
common value for binding in the absence of competitor IFN and a 
common value for the non-specific binding; curve B was not con-
strained (see Section 2 for discussion). 
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Fig. 4. Scattergram showing the IC50 values for independent experiments. Each IC50 value is derived from an independent competition curve 
like those in Figs. 2 and 3. 
with Figs. 2B and 3B; Table 2). The selectivity of type I 
ligands was examined by their inhibition of [32P]IFN-oc2 bind-
ing to COS cells expressing IFNAR-2b or -2c (Table 2; Figs. 
2B and 3B). The mean calculated IC50 values for independent 
experiments were reproducible (Fig. 4), and produced signifi-
cant values for the IC50 for each ligand (Table 2). For IFN-oc2 
the mean IC50 is within experimental error (2-fold) in both 
sets of experiments shown in Table 2. This demonstrates that 
IFNAR-2b and -2c have experimentally indistinguishable 
binding affinity for IFN-cc2. The two ligand sets can be 
merged to give a rank order of inhibition: IFN-oo = IFN-
a 2 > I F N - a C o n l » I F N - a 8 > I F N - P » I F N - a l . The placement 
of IFN-aConl is somewhat tentative because of its experi-
mental variability. 
Similar competition experiments of type I IFNs were per-
formed with soluble IFNAR-2/Ig protein in a RLA (Table 2; 
Figs. 2A and 3A). Comparing the ligand specificities of 
IFNAR-2 expressed on COS cells or as a soluble protein, 
there is a good correspondence of the IC50 values and rank 
order for the diverse ligands tested, although there is a small 
(2-fold) discrepancy in the IC50 values for IFN-aConl. The 4-
fold discrepancy in the IC50 values for IFN-al in the two 
binding formats may reflect its low affinity and consequent 
fast dissociation rate; a fast dissociation rate increases the 
importance of some experimental variables, such as the slower 
washing times in the RLA format. Nevertheless, the measured 
binding of all ligands by IFNAR-2 expressed on COS cells 
appears to represent well the intrinsic binding properties 
of the IFNAR-2 extracellular domain as measured with the 
IFNAR-2/Ig soluble construct. 
3.3. Binding of IFNs to the IFNAR-1/IFNAR-2 complex 
The high-level co-expression of IFNAR-1 and IFNAR-2 on 
COS cells was used to investigate the ligand binding proper-
ties of the IFNAR-1/IFNAR-2 complex. In the competition 
experiments with diverse type I IFNs, two effects of co-ex-
pression of IFNAR-1 and IFNAR-2 are seen (e.g. Fig. 2C, 
Figs. 3C and 4; and Table 3, columns 1-3). First, the IC50 of 
all ligands decreases (Table 3, column 1), representing an in-
crease in ligand-binding affinity over that measured for cells 
transfected with IFNAR-2 alone (column 2). Second, compar-
ing the IC50 of each ligand with co-expressed IFNAR-1 and 
IFNAR-2, vs. IFNAR-2 alone, there are significant differen-
ces in the degree to which the IC50 values decreases (Table 3, 
column 3). The IC50 for the low affinity IFN-al increases 
most in the presence of IFNAR-1, followed by IFN-a2, 
IFN-a8, and IFN-aConl. However, the effect of IFNAR-1 
on the binding of IFN-co and IFN-P is the smallest, only 3-7-
fold. (The equivalence within experimental error of IFNAR-
2b and IFNAR-2c was demonstrated in less extensive experi-
Table 2 
Inhibition (IC50, molar) by type I interferons of [32P]IFN-a2 binding to soluble IFNAR-2/Ig, or COS cells transfected with IFNAR-2 
Ligand set 1: 
IFN-a2 
IFN-a8 
IFN-al 
IFN-P 
Ligand set 2: 
IFN-a2 
IFN-aConl 
IFN-co 
IFNAR-2/Ig 
4.4 Xl0~9 
6.3 XlO"9 
1.1 X10"6 
1.3 XlO"8 
2.2 X10~9 
1.2 XlO"8 
1.4 Xl0~9 
(3.2-6.3) 
(5.9-7.8) 
(0.2-5.5) 
(0.5-3.3) 
(1.9-2.6) 
(1.0-1.5) 
(2.1-5.2) 
IFNAR-2/COS 
2.2 X10~9 
8.6 XlO"9 
2.6 X10~7 
1.9 XlO"8 
3.5 X10~9 
8.9 XlO"9 
2.6X10~9 
(0.7-6.4) 
(7.7-9.5) 
(0.6-10) 
(1.8-2.0) 
(1.4-8.7) 
(2.1-38) 
(0.9-7.6) 
Rat 
2.0 
0.7 
4.2 
0.7 
0.6 
1.3 
0.5 
io (soluble/COS) 
Values are the mean of several independent determinations of the IC50 (see Fig. 4 for individual IC50 values). Numbers in parentheses are the range 
of IC50 values at ± one standard deviation from the mean. Means were calculated from 3^1 independent measurements for the ligands in set 1, 
with the exception of IFN-P on IFNAR-2/Ig, which is the mean of two determinations. In ligand set 2, means for the transfected COS cells are 
from three determinations, whereas means for soluble IFNAR-2/Ig were calculated from two determinations. COS transfections for ligand set 
1 utilized IFNAR-2b, whereas ligand set 2 transfections used the IFNAR-2c construct. 
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merits for all ligands; data not shown.) Thus, there is a clear 
increase in ligand affinity by co-expressing IFNAR-1 with 
IFNAR-2, but the effect varies significantly for different li-
gands. 
4. Discussion 
The ability of diverse IFNs to differentially activate cells 
through a common receptor poses the issue of how the recep-
tor differentially recognizes these ligands and transmits signals 
of the appropriate type, strength or duration. Here we have 
examined the roles of IFNAR-1 and IFNAR-2 in differential 
ligand binding and recognition, with the goal of reconstituting 
the binding parameters and patterns seen on human cells. 
The experiments exploited the high level expression of 
IFNAR-1 and IFNAR-2 provided by the COS transient ex-
pression system, as indicated by greatly elevated ligand bind-
ing (Fig. 1; Table 1), and confirmed by flow cytometric anal-
ysis of cell surface receptors (data not shown). Thus, the 
binding to the ectopic receptors was clearly distinguishable 
from the low-level binding to the endogenous COS receptor. 
Moreover, the strong agreement of the binding parameters for 
the soluble IFNAR-2/Ig fusion protein and IFNAR-2 ex-
pressed on COS cells (Table 2) confirms that the intrinsic 
ligand binding properties of the transfected receptors are 
being measured. However, the natural sensitivity of monkey-
derived COS cells to human IFNs precludes correlative func-
tional data of cellular activation resulting from transfected 
human IFNAR proteins. 
IFNAR-2, whether expressed on COS cells or as the soluble 
IFNAR-2/Ig 'immunoadhesin', has moderately high but dif-
ferential affinity for five of the type I IFNs examined here, 
with IC50 values in the range of 1.5 XlO"9 to 2X10"8 M 
(Table 2). Only IFN-al has a very low affinity (IC50 of 
2 .6xl0~ 7 to 1.1 XlO - 6). These results extend previous qual-
itative results that soluble IFNAR-2 can bind IFN-a2, IFN-
aB, IFN-aC and IFN-P [19], and demonstrate the fidelity of 
IFNAR-2 expressed on COS cells as a binding substrate. 
The IFNAR-1 /IFNAR-2 complex binds IFN-oc2 with high-
er affinity than does IFNAR-2 alone (Table 1). This is qual-
itatively consistent with previous reports [20-22,31], although 
we observed a smaller increase in affinity than did workers 
using rodent cells. However, these reports also differed among 
them in their K& values for the binding of radiolabeled IFN-
oc2 or -a8 to the IFNAR-1 /IFNAR-2 complex expressed in 
different murine cells and at different expression levels; two 
reports suggested the existence of both high-affinity and low-
affinity components [20,31]. It is difficult to clarify the quan-
titative differences among the reports, although experimental 
variation should not be underestimated. 
While the IFNAR- l/IFNAR-2 complex binds all tested li-
gands with higher affinity (lower IC50) than does IFNAR-2 
alone (Table 3), the addition of IFNAR-1 to IFNAR-2 pro-
duces differential effects on the IC50 values of the various 
ligands. The strongest effects (12-22-fold) are on the binding 
of IFN-as, with smaller effects (3-7-fold) measured for IFN-P 
and IFN-o), the less 'typical' members of the type I IFN 
family. 
Particularly interesting are the differences in the ligand spe-
cificity of COS cells cotransfected with IFNAR-1 and 
IFNAR-2 compared with human Daudi cells (Table 3, col-
umns 2, 4, 5). Although the IC50 values for IFN-oc2 and -oc8 
are comparable for transfected COS cells and Daudi cells, 
those for IFN-al , -aConl and IFN-co are about five times 
higher (lower affinity) on the transfected COS cells, and the 
value for IFN-p is about 18 times higher (lower affinity) than 
on Daudi cells. The discrepancy for IFN-p of IC50 values 
between Daudi cells and COS cells co-expressing IFNAR-1 
and IFNAR-2 is noteworthy in view of reports of IFN-P-
specific effects [32-38]. Other cellular factors that may modu-
late type I IFN receptor binding have been reviewed [39]. 
A direct comparison of our results with previous binding 
and competition studies on human cells is complicated by the 
variety of cell types and conditions used. However, in all 
studies, IFN-al has the weakest binding and lowest biological 
activity of all type I IFNs for human cells [40-45]. On the 
other hand, IFN-aConl, a construct based on the consensus 
sequence of the human IFN-a family, is reported to have 
biological specific activity on some cells almost 10-fold higher 
than other IFN-as (reviewed in [46]). While the basis for this 
high activity is said to be higher affinity interactions with the 
receptor [43,47], previous experimental results were incom-
plete [43], and our experiments did not show IFN-aConl to 
be distinguished by an unusually high affinity for IFNAR-2, 
for the IFNAR-l/IFNAR-2 complex on COS cells, or for 
Daudi cells (Tables 2 and 3). 
Our current results demonstrate that IFNAR-2 binds the 
array of type I ligands with moderate affinity, and manifests 
Table 3 
Inhibition (IC50, molar) by type I interferons of [32P]IFN-oc2 binding to soluble IFNAR-2/Ig, transfected COS cells and Daudi cells 
Ligand set 1: 
IFN-a2 
IFN-a8 
IFN-al 
IFN-P 
Ligand set 2: 
IFN-a2 
IFN-aConl 
IFN-co 
1. IFNAR-2/COS 
2.2X10"' 
8.6X10"' 
2.6 XlO"7 
1.9 XlO"8 
3.5X10"' 
8.9X10"' 
2.6X10"' 
(0.7-6.4) 
(7.7-9.5) 
(0.6-10) 
(1.8-2.0) 
(1.4-8.7) 
(2.1-38) 
(0.9-7.6) 
2. IFNAR-(l+2)/COS 
1.8X10"'° 
7.9X10"'° 
1.2 X10"8 
5.9X10"' 
1.9X10"'° 
6.8X10"'° 
3.7X10"'° 
(0.7-4.4) 
(4.1-15) 
(0.8-1.7) 
(3.1-11) 
(1.2-2.8) 
(2.0-23) 
(3.5-3.9) 
3. Ratio 1/2 
12 
11 
22 
3 
18 
13 
7 
4. Daudi 
1.3X10"10 
3.4 XlO"10 
2.3X10"' 
3.2 XlO"10 
1.4X10"'° 
1.4X10"10 
0.6X10"'° 
(0.9-1.7) 
(1.7-6.7) 
(1.6-3.4) 
(0.9-11) 
5. Ratio 2/4 
1.4 
2.3 
5.2 
18.4 
1.4 
4.8 
6.2 
Values are the mean of several independent determinations of the IC50. Numbers in parentheses are the range of IC50 values at ± one standard 
deviation from the mean. Means were calculated from 3-4 independent measurements for the ligands in set 1, with the exception of IFN-p on 
IFNAR-2/Ig, which is the mean of two determinations. In ligand set 2, means for the transfected COS cells are from three determinations, whereas 
means for soluble IFNAR-2/Ig were calculated from two determinations. For Daudi cells, IC50 values are an average of three determinations for 
ligands in set 1 (except for IFN-P, which represents two experiments), and represent a single measurement for ligands in set 2. COS transfections for 
ligand set 1 utilized IFNAR-2b, whereas ligand set 2 transfections used the IFNAR-2c construct. 
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differential affinity. I F N A R - 1 was previously shown to bind 
I F N s weakly but directly, both when expressed on Xenopus 
laevis oocytes [6], and as a soluble ectodomain [7], confirming 
earlier inferences of such interactions [5,11,12,48,49]. The cur-
rent experiments demonstrate that I F N A R - 1 contributes both 
to enhancing the affinity of the IFNAR-1 / IFNAR-2 complex 
and to modulat ing the differential recognition of type I IFNs . 
The fact that both I F N A R - 1 and I F N A R - 2 bind directly to 
I F N s and presumably recognize different regions of the I F N is 
consistent with previous suggestions that type I IFNs have 
two or three receptor binding domains (e.g. [50-54]). It is 
now important to determine the I F N A R - 1 and I F N A R - 2 
binding sites on type I IFNs , and vice versa. It is also impor-
tant to ascertain whether contributions to the binding of some 
or all type I ligands, particularly IFN-(3, are made by other 
cellular components, and whether there are variations in the 
ligand specificity between cell types. 
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